Condition: Pancreatic Cancer Non-resectable
Interventions: Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel; Drug: Placebo + Gemcitabine + Nab-paclitaxel
Sponsor: FibroGen
Recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer
June 4, 2019ClinicalTrials.govComments OffHepatology(Liver, Pancreatic, Gall Bladder)Advanced | Cancer | Chemotherapy | Combination | Efficacy | Evaluation | Gemcitabine | Locally | Nabpaclitaxel. | NEOADJUVANT | Pamrevlumab | Pancreatic | Safety | Treatment
Comments
